ArticleBMC cancer2026
Off-label drug use in oncology practice: a nationwide cross-sectional survey among Turkish medical oncologists.
Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundOff-label drug use is a common but understudied phenomenon in oncology. The extent to which oncologists are aware of the regulatory status of the drugs they prescribe remains unclear. This study aimed to assess knowledge, attitudes, barriers, and self-reported practices regarding off-label drug use among medical oncologists in Türkiye, and to evaluate the discrepancy between actual prescribing behavior and awareness of off-label status.
methodsA cross-sectional, web-based survey was conducted among medical oncologists across Türkiye between October 2025 and February 2026. The questionnaire comprised 37 items covering demographics, knowledge and perceptions, decision-making resources, barriers, informed consent practices, self-reported off-label rates, and 15 clinical scenarios representing drug–indication pairings that are all off-label per the Turkish regulatory authority (TİTCK). Descriptive statistics, chi-square tests, Mann-Whitney U tests, and Kruskal-Wallis tests were used for analysis.
resultsA total of 192 oncologists from 41 cities participated (mean age 42.9 ± 9.1 years; 52.6% senior faculty). While 92.2% reported being at least familiar with off-label use, only 35.4% rated themselves as highly knowledgeable. The most frequently used off-label drugs were gemcitabine in cholangiocarcinoma (99.5% regular use), carboplatin in endometrial cancer (97.3%), and oxaliplatin in pancreatic cancer (96.8%). The primary barrier was reimbursement issues (90.1%). Critically, when asked to estimate how many of the 15 presented scenarios were off-label (all 15 are), only 5.2% correctly identified all as off-label, and 43.8% estimated that only 1–5 were off-label. No significant differences were observed by seniority level, experience, or patient volume.
conclusionsOff-label drug use is highly prevalent in Turkish oncology practice, yet oncologists substantially underestimate the extent of off-label prescribing. This awareness gap has significant implications for informed consent, medicolegal liability, and regulatory policy. Educational interventions and clearer regulatory frameworks are needed to bridge this gap.
trial registrationNot applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.